CRIS Current Research Information System

DE LORENZO, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.782
AS - Asia 2.402
EU - Europa 1.976
AF - Africa 228
SA - Sud America 109
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.501
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.744
SG - Singapore 811
CN - Cina 793
IT - Italia 514
VN - Vietnam 305
GB - Regno Unito 295
SE - Svezia 290
DE - Germania 216
HK - Hong Kong 135
KR - Corea 126
IN - India 122
NL - Olanda 117
IE - Irlanda 101
CI - Costa d'Avorio 93
CH - Svizzera 89
RU - Federazione Russa 86
BR - Brasile 69
FR - Francia 59
SC - Seychelles 46
FI - Finlandia 39
TG - Togo 38
AT - Austria 28
CA - Canada 27
JO - Giordania 27
UA - Ucraina 25
BG - Bulgaria 22
NG - Nigeria 21
ZA - Sudafrica 21
EE - Estonia 18
ID - Indonesia 16
BE - Belgio 15
TR - Turchia 15
PL - Polonia 14
AR - Argentina 13
GR - Grecia 13
JP - Giappone 11
LT - Lituania 8
PS - Palestinian Territory 8
BD - Bangladesh 7
EC - Ecuador 7
RO - Romania 7
CL - Cile 6
IQ - Iraq 6
MX - Messico 6
ES - Italia 5
UZ - Uzbekistan 5
EG - Egitto 4
NI - Nicaragua 4
PE - Perù 4
VE - Venezuela 4
CO - Colombia 3
HR - Croazia 3
PT - Portogallo 3
PY - Paraguay 3
SA - Arabia Saudita 3
IR - Iran 2
LB - Libano 2
MD - Moldavia 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PK - Pakistan 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
CG - Congo 1
CM - Camerun 1
CZ - Repubblica Ceca 1
DJ - Gibuti 1
DK - Danimarca 1
HT - Haiti 1
HU - Ungheria 1
KE - Kenya 1
KZ - Kazakistan 1
LV - Lettonia 1
MA - Marocco 1
PH - Filippine 1
SK - Slovacchia (Repubblica Slovacca) 1
TV - Tuvalu 1
TW - Taiwan 1
Totale 7.501
Salva come PNG Salva come JPEG
Città #
Singapore 572
Hefei 316
Ashburn 300
Dallas 290
Southend 255
Chandler 238
Fairfield 225
Dong Ket 162
Hong Kong 134
Woodbridge 128
Houston 124
Seoul 121
Dublin 101
Wilmington 101
Beijing 95
Abidjan 93
Seattle 92
Bologna 87
Santa Clara 87
Bern 82
Princeton 82
Cambridge 77
Ann Arbor 75
Boardman 62
New York 49
Turin 40
Rome 39
Lomé 38
Nanjing 34
Helsinki 33
Ho Chi Minh City 32
Los Angeles 32
Milan 32
Frankfurt am Main 30
Berlin 28
Hanoi 28
Amman 27
Bengaluru 27
Redondo Beach 23
Westminster 23
Sofia 22
San Diego 21
Buffalo 20
Redmond 18
Abeokuta 17
Padova 15
Tongling 15
Vienna 15
Brussels 14
Chicago 14
Toronto 14
London 13
São Paulo 13
Jakarta 12
Munich 12
Düsseldorf 11
Ravenna 11
Redwood City 11
Shanghai 11
Shenyang 11
Tokyo 11
Warsaw 11
Florence 10
Guangzhou 10
Jinan 10
Des Moines 9
Groningen 9
Olalla 9
Bremen 8
Changsha 8
Halhul 8
Istanbul 8
Saint Petersburg 8
Amsterdam 7
Falkenstein 7
Forlì 7
Jacksonville 7
Medford 7
Montreal 7
Norwalk 7
Torino 7
Wuhan 7
Hebei 6
Kunming 6
Nuremberg 6
Pune 6
Yubileyny 6
Denver 5
Hải Dương 5
Moscow 5
Mountain View 5
Nanchang 5
Phoenix 5
Qingdao 5
San Francisco 5
The Dalles 5
Zhengzhou 5
Ankara 4
Bari 4
Brooklyn 4
Totale 4.978
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 402
Adjuvant treatment in biliary tract cancer 317
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 272
SUSTAINED COMPLETE RESPONSE OF ADVANCED HEPATOCELLULAR CARCINOMA WITH METRONOMIC CAPECITABINE: A REPORT OF THREE CASES 265
An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone 260
Adjuvant chemotherapy for resected colorectal cancer metastases: literature revision and meta-analysis 231
Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients 217
Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib. 209
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 202
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 198
Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention 189
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 184
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 182
Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis 181
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 179
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 176
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 176
In Reply 171
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 169
Cholangiocarcinoma: From risk to prevention? 159
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. 159
Postsorafenib systemic treatments for hepatocellular carcinoma: Questions and opportunities after the regorafenib trial 154
The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation 153
Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report. 148
An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib 140
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 138
Adjuvant Treatment and Follow-up Strategies 134
Treatment of combined hepatocellular and cholangiocarcinoma 128
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster 124
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 122
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? 119
Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis 116
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 116
Regorafenib for the treatment of hepatocellular carcinoma 112
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 111
Should patients on levothyroxine therapy be screened for pancreatic cancer? 108
Combination makes strength: a narrative review of transarterial radioembolization plus immune checkpoint inhibitors for hepatocellular carcinoma 105
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 103
Immunotherapy with checkpoint inhibitors for hepatocellular carcinoma: Where are we now? 100
Non-alcoholic steatohepatitis as a risk factor for intrahepatic cholangiocarcinoma and its prognostic role 97
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma 97
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 88
Trend of rifampicin resistant, MDR and XDR tuberculosis in Italy, 2009–2016 88
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) 85
Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain? 84
Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development 79
null 75
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma 70
Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second-line clinical trials 68
Oral oxycodone/naloxone for pain control in cirrhosis: Observational study in patients with symptomatic metastatic hepatocellular carcinoma 57
null 56
Microbiota, NASH, HCC and the potential role of probiotics 47
Totale 7.720
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.564
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.564
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021473 0 0 0 0 0 54 36 46 69 41 28 199
2021/2022961 112 46 46 64 74 29 30 67 84 61 219 129
2022/20231.180 114 169 56 115 84 77 46 68 207 58 60 126
2023/2024327 34 51 16 28 16 69 13 19 17 26 21 17
2024/20251.496 68 161 145 89 144 53 122 110 49 150 121 284
2025/20262.096 374 432 539 282 319 150 0 0 0 0 0 0
Totale 7.720